Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Up 34.6% in March

Lonza Group Ag (OTCMKTS:LZAGY) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 5,253 shares, a growth of 34.6% from the March 15th total of 3,903 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 171,137 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analyst Weigh In

LZAGY has been the subject of several recent analyst reports. Zacks Research upgraded shares of Lonza Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. Royal Bank Of Canada raised shares of Lonza Group from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, February 11th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Lonza Group Price Performance

Lonza Group stock opened at $68.14 on Thursday. The stock’s 50 day moving average price is $65.00 and its two-hundred day moving average price is $67.07. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.24. Lonza Group has a 52-week low of $58.53 and a 52-week high of $73.85.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.